Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in its U.S.

Drug developer Maze Therapeutics said on Monday it was targeting a valuation of as much as $728.1 million in its initial ...

The IPO trend remains robust in 2025, driven by strong retail investor interest and a shift from FPIs to the primary market.

Metsera Inc. is seeking to raise $292 million in an initial public offering, joining a clutch of health-care firms set to ...

Maze Therapeutics has set out plans for a $131 million IPO as the company prepares to start dosing its lead kidney drug in a ...

Czech steam-turbine manufacturer Doosan Skoda Power AS launched an initial public offering, touting an outlook for high ...

Metsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks to fund a phase 3 trial of its ...

The stock market trading debut comes as incoming President Trump has said he plans to boost America’s energy production.

Venture Global's IPO represents a test for investor appetite for fossil fuel projects in the Trump administration.

Snag is, Cheniere’s two export terminals are already advanced enough to generate several billion dollars in cash flow, much of which is already flowing in dividends to shareholders. Venture Global is ...

More generally, markets have a way of recalibrating, and Venture Global’s IPO offers a nuanced lesson. It’s a reminder that valuations aren’t fixed by management or banker decree, but rather hammered ...

The listing was a book-built IPO and comprised a fresh issuance of 7.5 million shares. The price band for the issue was Rs ...